Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Long-Term Deferred Tax (2018 - 2024)

Historic Long-Term Deferred Tax for OptimizeRx (OPRX) over the last 7 years, with Q4 2024 value amounting to $4.5 million.

  • OptimizeRx's Long-Term Deferred Tax rose 355.08% to $4.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 million, marking a year-over-year increase of 355.08%. This contributed to the annual value of $4.5 million for FY2024, which is 355.08% up from last year.
  • OptimizeRx's Long-Term Deferred Tax amounted to $4.5 million in Q4 2024, which was up 355.08% from $4.3 million recorded in Q4 2023.
  • In the past 5 years, OptimizeRx's Long-Term Deferred Tax ranged from a high of $10.5 million in Q4 2022 and a low of $4.3 million during Q4 2023
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $4.5 million (2020), whereas its average is $6.4 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first surged by 7330.69% in 2021, then plummeted by 5866.37% in 2023.
  • Quarter analysis of 5 years shows OptimizeRx's Long-Term Deferred Tax stood at $4.5 million in 2020, then soared by 73.31% to $7.9 million in 2021, then skyrocketed by 33.11% to $10.5 million in 2022, then tumbled by 58.66% to $4.3 million in 2023, then grew by 3.55% to $4.5 million in 2024.
  • Its Long-Term Deferred Tax stands at $4.5 million for Q4 2024, versus $4.3 million for Q4 2023 and $10.5 million for Q4 2022.